David B.  Weiner net worth and biography

David Weiner Biography and Net Worth

Dr. David B. Weiner Ph.D. serves as Director of the Company. Dr. Weiner qualifies to serve on our Board as he is a recognized leader in immunology as well as in gene vaccines and therapy. Since 2016, Dr. Weiner has served as Executive Vice President and Director of the Vaccine Center at The Wistar Institute, the nation’s first independent biomedical research institute, which is also an NCI-designated Cancer Center and an international leader in cancer, immunology and infectious disease research. Dr. Weiner is also the W. W. Smith Charitable Trust Professor of Cancer Research at The Wistar Institute. Previously, Dr. Weiner was Professor of Pathology & Laboratory Medicine at the University of Pennsylvania and Chair of the Gene Therapy and Vaccine Program at the University’s Perelman School of Medicine. He has more than 350 peer-reviewed publications in scientific journals, including mainstream scientific journals such as Scientific American, and has been designated by the Institute for Scientific Information as one of the top-cited scientists in the world. An inventor and holder of more than 100 issued and pending U.S. patents, Dr. Weiner has received numerous honors including election as a fellow to the American Association for the Advancement of Science in 2011 and the International Society for Vaccines in 2012. He was the recipient of the NIH Director’s Transformative Research Award and received the Vaccine Industry Excellence Award for Best Academic Research Team in 2015 at the World Vaccine Congress. Dr. Weiner was honored with the prestigious Hilleman Lectureship in 2015 at the Children’s Hospital of Philadelphia Grand Rounds session and received a Stone Family Award from Abramson Cancer Center for his groundbreaking work on DNA vaccines for cancer immune therapy. Dr. Weiner holds a Ph.D. in developmental biology from the University of Cincinnati College of Medicine, an M.S. in biology from the University of Cincinnati and a B.S. in biology from SUNY at Stony Brook in Stony Brook, New York.

What is David B. Weiner's net worth?

The estimated net worth of David B. Weiner is at least $25,090.40 as of March 13th, 2023. Dr. Weiner owns 6,320 shares of Inovio Pharmaceuticals stock worth more than $25,090 as of November 21st. This net worth evaluation does not reflect any other assets that Dr. Weiner may own. Learn More about David B. Weiner's net worth.

How do I contact David B. Weiner?

The corporate mailing address for Dr. Weiner and other Inovio Pharmaceuticals executives is 660 W. GERMANTOWN PIKE SUITE 110., PLYMOUTH MEETING PA, 19462. Inovio Pharmaceuticals can also be reached via phone at (267) 440-4200 and via email at [email protected]. Learn More on David B. Weiner's contact information.

Has David B. Weiner been buying or selling shares of Inovio Pharmaceuticals?

David B. Weiner has not been actively trading shares of Inovio Pharmaceuticals within the last three months. Learn More on David B. Weiner's trading history.

Who are Inovio Pharmaceuticals' active insiders?

Inovio Pharmaceuticals' insider roster includes Simon Benito (Director), Laurent Humeau (Insider), Peter Kies (CFO), Jong Kim (CEO), Jacqueline Shea (COO), David Weiner (Director), and Lota Zoth (Director). Learn More on Inovio Pharmaceuticals' active insiders.

David B. Weiner Insider Trading History at Inovio Pharmaceuticals

See Full Table

David B. Weiner Buying and Selling Activity at Inovio Pharmaceuticals

This chart shows David B. Weiner's buying and selling at Inovio Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Inovio Pharmaceuticals Company Overview

Inovio Pharmaceuticals logo
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
Read More

Today's Range

Now: $4.13
Low: $3.97
High: $4.24

50 Day Range

MA: $5.61
Low: $3.97
High: $6.82

2 Week Range

Now: $4.13
Low: $3.85
High: $14.75

Volume

339,453 shs

Average Volume

403,906 shs

Market Capitalization

$107.79 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83